SREK1 decrease in Huntington’s disease lowers TAF1 mimicking X-linked dystonia parkinsonism

Takeaway

  • Pathogenic SREK1 decrease in Huntington’s disease and the resulting deficit in TAF1 could be a mechanism for striatal neurodegeneration and a target for therapeutic intervention.

Why this matters

  • SRSF6 activity in the striatum is altered in patients with Huntington’s disease. SREK1 is a direct interactor and regulator of SRSF6, as well TAF1. Reduced TAF1 expression due to a retrotransposon insertion mutation causes X-linked dystonia parkinsonism, similar to Huntington’s disease.

  • The results of this study indicate reduced SREK1 lead to a reduction in TAF1 levels, which can be rescued by overexpression of SREK1. In mice models, overexpression of SREK1 also attenuated the motor coordination deficit associated with Huntington’s disease. Together, the findings of this study implicate decreased SREK1 expression, and the resulting deficit in TAF1, in the pathogenesis of Huntington’s disease. This is evidence of a mechanistic convergence with X-linked dystonia parkinsonism and poses new targets for therapeutic intervention.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.